Author: Pradip Tikhe

Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer, and Brian Blakey, Chief Business Officer, will participate in a fireside chat at the Baird Biotech Discovery Series on Tuesday, December 5, 2023, at 11:30 AM ET. Stealth leadership will be joined by Dr. Arshad Khanani, Director of Clinical Research, Sierra Eye Associates, to discuss data from the Company’s Phase 2 ReCLAIM-2 trial of elamipretide in dry age-related macular degeneration (dry AMD) and provide an update…

Read More

Bio-Techne (NASDAQ:TECH) has reported a 2% organic growth in Q1 of fiscal year 2024, despite facing challenges in the biotech funding environment and economic hurdles in China. The company’s growth pillars, including GMP proteins, ExoDx prostate, and Protein Simple, have shown strong performance. Kim Kelderman has been appointed as the incoming CEO, effective February 1, 2024, while Chuck Kummeth will retire on July 1, 2024. The company remains committed to its ESG initiatives and corporate sustainability. Key takeaways from the call include: Bio-Techne’s Q1 revenue was $276.9 million, a 2% increase on an organic basis, with adjusted EPS at $0.41,…

Read More

It’s the time of year when the Fierce Biotech team sticks its shovel into fresh soil to bury another year’s worth of biotechs. Though the list is ritualistic, it’s hardly ceremonious. It marks the difficult decision many drug developers had to make after funds ran dry or scientific leads reached dead ends or both. And, in the industry’s current financing environment, an exorbitant amount of biotechs have reached this point. All told, we tallied 22 biotechs that shuttered this year or disclosed plans to do so, more than three times as many as last year’s seven companies. Maybe it’s the…

Read More

We feel now is a pretty good time to analyse BRAIN Biotech AG’s (ETR:BNN) business as it appears the company may be on the cusp of a considerable accomplishment. BRAIN Biotech AG offers Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The €88m market-cap company posted a loss in its most recent financial year of €6.6m and a latest trailing-twelve-month loss of €6.7m leading to an even wider gap between loss and breakeven. Many investors are wondering about the rate at which BRAIN Biotech will turn a profit, with the big question being “when…

Read More

GIFT Nifty on the NSE IX traded 83 points, or 0.43 per cent, higher at 19,509.5, signaling that Dalal Street was headed for positive start on Monday. Here’s a slew of stocks that will be in focus today for various reasons. Q2FY24 earnings today: Torrent Pharmaceuticals, Lloyds Metals and Energy, PNB Housing Finance, Alok Industries, Mahindra Holidays & Resorts India, Kewal Kiran Clothing, Mahindra Logistics, New Delhi Television, and Ganesha Ecoverse. ICICI Bank: The private lender, on Saturday, reported a 36 per cent rise in standalone net profit to Rs 10,261 crore for the September 2023 quarter, aided by an improvement in…

Read More

Rossari Biotech was trading almost 3 percent lower in the afternoon trade on October 23 on profit booking after the company over the weekend reported a 37 percent year-on-year (YoY) increase in net profit in the July-to-September quarter. Rossari Biotech reported a net profit of Rs 32.9 crore, the company said in an exchange filing on October 21. Revenue was at Rs 483.5 crore, up 13.7 percent from the year-ago quarter. The EBITDA was up 12.6 percent at Rs 63.6 crore. Revenue from the home personal care and performance chemicals  (HPCC) segment grew 20 percent YoY to Rs 367.1 crore in Q2FY4. The…

Read More

The last day of trading for Concord Biotech saw an open price of ₹1184.9 and a close price of ₹1184.75. The stock had a high of ₹1189.95 and a low of ₹1160. Concord Biotech closed today at ₹1158, down -1.25% from yesterday’s ₹1172.65 The market capitalization for Concord Biotech is ₹12338.44 crore. The 52-week high for the stock is ₹1212.3 and the 52-week low is ₹900. The stock had a trading volume of 3139 shares on the BSE.

Read More

Three years from establishment Stramsen Biotech, Inc, one of the leading plant-based biotech start-up companies, is raising $10 million at a $807 million valuation according to a third-party valuation company based in Los Angeles, California – Stonebridge Advisory. Stramsen Biotech team believes that other valuation methods or models may show the company’s value at around $5 billion. Currently officially valued at $807 million, Stramsen Biotech is now one of the world’s largest Biotech Start-ups based on the company’s pipeline. According to the GLOBE NEWSWIRE — The Global Herbal Medicine Market size reached USD 185.86 billion in 2020. The market valuation…

Read More

Singapore set out to become a global biotech hub back in 2000, and, although still awaiting its big success story in the industry, it is currently a leading hub in the APAC region for R&D, biopharma manufacturing, and commercial operations, with a growing startup ecosystem that includes numerous biotech companies. In 2000, the government in Singapore made biomedical research the fourth pillar of the city’s state economy, known as the National Biomedical Science Strategy. Then, in 2003, under the initiative, the country established Biopolis, which is a custom-built biomedical R&D hub. Over the next 20 years or so, billions of…

Read More

uropean Union lawmakers are being urged to avoid too much risk aversion from holding back the potential of the homegrown biotech sector. Developments in biotech could be transformative in a range of critical sectors. Beyond huge promise in healthcare, innovative, low carbon applications in areas like agriculture and food systems and energy production could help address pressing environmental and sustainability challenges. But there’s concern among some local operators that the bloc’s current approach could cap potential biotech benefits — especially in the context of the urgency required to tackle the climate crisis. “The main regulatory challenges for the EU’s biotech…

Read More